Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 589
- Registration Number
- NCT01570686
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT01568775
- Locations
- 🇩🇪
Charité Universitätsmedizin, Berlin, Germany
Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 24
- Registration Number
- NCT01519635
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries
- Conditions
- HypertensionDiabetes
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Registration Number
- NCT01480791
- Locations
- 🇨🇦
Cardiovascular Prevention Centre, Jewish General Hospital, Montreal, Quebec, Canada
Shiga Microalbuminuria Reduction Trial-2
- Conditions
- Type 2 Diabetes MellitusHypertension
- Interventions
- Drug: any angiotensin receptor blockers
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Shiga University
- Target Recruit Count
- 237
- Registration Number
- NCT01461499
- Locations
- 🇯🇵
Shiga University of Medical Science, Otsu, Shiga, Japan
Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
- Conditions
- Arterial Hypertension
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Stiftung Institut fuer Herzinfarktforschung
- Target Recruit Count
- 15337
- Registration Number
- NCT01454583
Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
- Conditions
- Kidney DiseaseKidney Failure, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01437943
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension
- Conditions
- HypertensionAbdominal Aortic Aneurysm
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 3
- Registration Number
- NCT01425242
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Noden Pharma
- Target Recruit Count
- 106
- Registration Number
- NCT01420068
- Locations
- 🇹🇷
Novartis Investigative Site, Ankara, Turkey
Aliskiren Effect on Aortic Plaque Progression
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 71
- Registration Number
- NCT01417104
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.